Long-term vascular health effects of cancer and its treatment

Cancer survivors face higher risks of heart disease, stroke, and other vascular problems long after treatment ends, and the reasons remain poorly understood. This matters because the number of cancer survivors is large and growing—over half a million in the UK alone, according to the abstract—yet current follow-up care focuses almost entirely on cancer recurrence, not on the cardiovascular and neurological damage that can emerge years later. The researcher has already shown that survivors of most cancer types have elevated risks of cardiovascular disease beyond what smoking and other shared risk factors explain. The key unknowns are what drives those risks—whether specific chemotherapy drugs, radiotherapy, or treatment-related changes in blood pressure and body weight are responsible—and whether the same mechanisms also increase rates of dementia and chronic kidney disease. If this research succeeds, it could change how survivors are monitored and treated after cancer. Instead of a one-size-fits-all approach, clinicians might offer targeted screening for heart or kidney problems based on the specific cancer therapy a patient received. The findings could also inform public health guidelines on managing blood pressure and weight in survivors, potentially preventing thousands of cases of vascular dementia and kidney failure. The work draws on UK Biobank data from 500,000 participants and new national cancer treatment records, giving it unusual statistical power to separate treatment effects from other risk factors.